
Biogen’s Alzheimer’s Drug Gets FDA Fast Track
Summary This article discusses Biogen’s experimental Alzheimer’s drug, BIIB080, receiving FDA Fast Track designation. The drug targets tau protein, a key factor in Alzheimer’s progression, and has shown promising results in early trials. This designation […]